Global HIV Resistance: The Implications of Transmission

Slides:



Advertisements
Similar presentations
Antiretroviral Drug Resistance Anna Maria Geretti UCL Medical School & Royal Free Hampstead Medical School, London.
Advertisements

Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.
Slide #1 HIV Entry Inhibitors Trip Gulick, MD, MPH Director, Cornell HIV Clinical Trials Unit Associate Professor of Medicine Weill Medical College of.
April 15 Understanding HIV Treatment and adherence. The African Eye Trust HIV Treatment Information Event By Badru Male&Elijah Amooti.
Changing Therapy Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents published October 2006 AETC NRC Slide Set.
HIV AND HIV MUTANTS E. Chigidi and E. Lungu University of Botswana Private Bag 0022 Gaborone, Botswana.
6/28/00TPED1 Resistance Testing: What is it? What does it mean? How does drug resistance emerge? Overview of methods Advantages and disadvantages Current.
Young person with multi-class resistance: follow-up and management (with perspectives from well-resourced and resource-limited settings) Gareth Tudor-Williams.
Salvage Antiretroviral Therapy Guiding Principles, Strategies and the Role of Resistance Testing.
Clinical Significance of HIV-1 Drug Resistance
Combination Antiretroviral Therapy for HIV Infection by Ormrat Kampeerawipakorn.
ANTIRETROVIRAL RESISTANCE Jennifer Fulcher, MD, PhD.
KITSO AIDS Training Program
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
HIV Drug Resistance Impact on ART for the Pregnant Woman Elliot Raizes, MD CDC Division of Global HIV/AIDS June 18, 2012.
What do models estimate to be the impacts on HIV incidence of various percentages of people with HIV on ART ? National AIDS Trust Treatment as Prevention.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
Failure Therapy VIRAL RESITANCE ADHERENCE!!!!!!!!!!! DRUG INTERACTION.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
Switch to ATV/r + 3TC  SALT Study. ATV/r 300/100 mg qd + 2 NRTI (investigator-selected) N = 143 ATV/r 300/100 mg + 3TC 300 mg qd  Design Randomisation*
Virological predictors of clinical outcome Anna Maria Geretti Royal Free Hampstead NHS Trust & UCL Medical School London.
HIV-1 Resistance - Implications For Clinicians Joseph J. Eron Jr., MD Professor of Medicine University of North Carolina.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Predicting NNRTI Resistance – do polymorphisms matter? Nicola E Mackie 1, Lucy Garvey 1, Anna Maria Geretti 2, Linda Harrison 3, Peter Tilston 4, Andrew.
1 ARV Drug Resistance HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Regimen Selection to Support a “Public Health” Approach Anthony Amoroso, MD Assistant Professor of Medicine University of Maryland School of Medicine Institute.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.
TITAN = TMC114/r In Treatment-experienced pAtients Naïve to lopinavir
Update on HIV Therapy Elly T Katabira, FRCP Department of Medicine Makerere University Medical School Scaling up Treatment Programs: Issues, Challenges.
Detection of clinically relevant antiretroviral drug resistance mutations among treated patients undergoing testing at low levels of viremia AM Geretti.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.
Epidemiology of HIV Transmissed Drug Resistance Mutations. Amilcar Tanuri, MD, PhD. Head of Laboratório de Virologia Molecular, UFRJ, Brazil.
Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Maintenance therapy with Trizivir® after 6 months induction with Trizivir® plus either efavirenz or lopinavir/r in naïve patients. Trizefal study J. Mallolas*
Evaluation of the WHO immunologic criteria for treatment failure among adults on first-line HAART in south India Snigdha Vallabhaneni 1, Sara Chandy 2,
Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.
Transmitted drug resistance Pat Cane. Questions What is the level of TDR and is it changing? Are we measuring TDR accurately? Are more sensitive methods.
Long Term Therapeutic Success of Etravirine in Switch and Naive Patients L.Bull, M.Bower, M.Nelson Chelsea and Westminster Hospital, London.
Will Drug Resistance Jeopardize the National HIV Drug Resistance Programme? Prof. Tulio de Oliveira Africa Centre for Health and Population Studies, University.
HIV-1 Resistance - Implications For Clinicians Joseph J. Eron Jr., MD Professor of Medicine University of North Carolina.
Washington D.C., USA, July 2012www.aids2012.org Changing Patterns of NRTI and PI Resistance Mutations Between 2006 and 2011 in ART experienced SA.
Management of NRTI Resistance
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Treatment-Experienced Patients in Resource- Limited Settings Susan M. Graham Assistant Professor, Medicine.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
HAIVN Harvard Medical School AIDS Initiative in Vietnam
Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Frequency HIV-1 Drug Resistance Mutations and.
HIV co-receptor tropism in treatment-naïve patients: impact on CD4 decline and subsequent response to HAART Laura Waters, Sundhiya Mandalia, Adrian Wildfire,
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
#AIDS2016 Dolutegravir (DTG) plus Rilpivirine (RPV) in Suppressed Heavily Pretreated HIV-Infected Patients A. Díaz, J.L. Casado, F.
Switch to PI/r monotherapy
Dealing with Treatment Failure…..
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;
Etravirine versus Protease Inhibitor in ARV-Experienced TMC 125-C227
St Stephen’s Centre, Chelsea & Westminster Hospital, United Kingdom
Drug-resistant human immunodefiency virus
Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens.
Switch to DRV/r monotherapy
Comparison of NNRTI vs PI/r
Switch to LPV/r monotherapy
Switch to LPV/r monotherapy
ARV-trial.com Switch to ATV/r + RAL HARNESS Study 1.
ARV-trial.com Switch to FTC + ddI + EFV ALIZE 1.
Differential Detection of M184V/I Between Plasma Historical HIV Genotypes and Proviral DNA from PBMCs N Margot, R Ram, IR McNicholl, R Haubrich, C Callebaut.
ANTIRETROVIRAL RESISTANCE IN CLINICAL PRACTICE
Presentation transcript:

Global HIV Resistance: The Implications of Transmission Deenan Pillay, MD, PhD Professor of Virology Royal Free & University College Medical School University College London London, UK

Disclosures

Structure of Talk Basis of resistance Resistance in treated: prevalence and predictors Resistance in untreated: prevalence, risk groups, persistence, minority populations and consequences Potential for resistance in developing world

Replication Cycle of HIV maturation inhibitor reverse transcriptase inhibitors integrase inhibitors DS dna COMPLEX protease inhibitors CD4 attachment inhibitors fusion inhibitor chemokine receptor inhibitors HIV entry inhibitors

The Biological Basis of HIV Drug Resistance

Question: Drug resistance emerges during antiretroviral therapy Because the drug interacts with the virus to cause resistance mutations Because pre-existing variants of virus preferentially replicate in the presence of drug Regardless of the level of viral suppression achieved

Virological Response to Antiretroviral Therapy rebound 105 104 103 102 101 100 10-1 10-2 10-3 assay limit of detection Copies/mL Suppression

Selective Pressure of Therapy Drug-susceptible quasispecies Drug-resistant quasispecies Viral load Time

Selective Pressure of Therapy Treatment begins Drug-susceptible quasispecies Drug-resistant quasispecies Viral load Time

Selective Pressure of Therapy Treatment begins Drug-susceptible quasispecies Drug-resistant quasispecies Selection of resistant quasispecies Viral load Incomplete suppression Inadequate potency Inadequate drug levels Inadequate adherence Pre-existing resistance Time

Resistance Accumulates Mutations Fold Change Susceptible Resistant Determine clinical relevance for each drug

How Much Resistance in ARV Treated Individuals?

Prevalence of Resistance as a Proportion of Treated Patients important to place resistance in context of all TREATED patients Pillay et al. JID 2005;192:967-73.

Predictors of Resistance in ARV-treated Patients

Prevalence of Triple-class Drug Failure Over Calendar Time Treatment experienced at start of HAART Treatment naïve at start of HAART 1/97 1/98 1/99 1/00 1/01 1/02 1/03 1/97 1/98 1/99 1/00 1/01 1/02 1/03 Follow-up (n) 554 1482 1814 1944 1988 2029 2028 140 514 716 860 958 1174 1212 0 10 68 163 241 282 3 15 0 0 10 21 33 3 8 58 Triple-class treatment failure (n) Mocroft et al. JID 2004;190:1947–56.

Years from start of ART (≥3 drugs) Cumulative Risk of Triple-class Virologic Failure (incl boosted PIs) in 10,603 Patients Years from start of ART (≥3 drugs) 2 4 6 8 10 Extensive failure of: Nucleosides 4% 9% 15% 21% 28% PIs 2% 8% 11% 16% NNRTI 13% 20% 26% 31% 35% TCF 5% Extensive TCF 0% 1% 3% PI failure = boosted PIs; TCF = triple class failure Phillips et al. CROI 2007. Abst 532.

Resistance in Treated Individuals is… Decreasing since initiation of triple therapy Low in those using RTV boosted PIs Managed by new drugs within existing classes and new classes

Transmission of Resistance ARV treated individuals living longer Incident infections continue to increase worldwide Transmitted resistance well recognised in countries with wide ARV coverage

Transmission of Resistance in Europe (17 countries) SPREAD Route of Infection p-value OR CI IDU 6.8% 6/88 0.35 0.65 0.27 1.58 Origin / infect. in HPC 5.2% 10/193 0.046 0.49 0.24 0.99 Heterosexual 12.0% 30/246 0.38 1.24 0.76 2.02 MSM (reference) 10.0% 47/467 1.00 Origin / infect. in HPC* 5.2% 10/193 0.046 0.49 0.24 0.99 *HPC = high prevalence countries n=989; 22% recent infections Wensing et al. JID 2005;192:958-66.

Samples with IAS mutation(s) (%) In resource rich world, transmitted resistance appears to be stabilising or even reducing 14 Chronic infection 12 10 8 Samples with IAS mutation(s) (%) 6 4 Acute infection 2 1997 1998 1999 2000 2001 2002 2003 2004 2005 Year of sample UK Collaborative Group on HIV Drug Resistance. AIDS 2007;21:1035-9.

Persistence of Transmitted Resistance in Primary HIV Infection Persistent resistance n=11 Primary resistance n=2 Reversion to wild type US; F/U median 9 months n=14 Persistent resistance n=16 Primary resistance n=2 Reversion to wild type UK; F/U up to 3 years Variable persistence according to mutations: TAMs persist, K103N persists, PI persist, MDR persist Little et al. 11th CROI 2004, San Francisco, CA. Abs 36LB. Pao et al. JAIDS 2004;37:1570-3.

In resource rich world... Rates of transmitted resistance stabilising or reducing Transmitted resistant species persist prior to initiating treatment, and represents a risk for onward transmission

Implications of ARV Rollout in Resource Poor World for Resistance

Implications of HAART Without Virological Monitoring: Therapy Failure? Increasing Resistance Implications of HAART Without Virological Monitoring: Therapy Failure? Treatment onset Virological failure (>1000c/mL) Clinical failure (AIDS events) VL 1000 Months Years CD4 count VL

Resistance Following First-line ART Country Most common ART regimen Other drugs % failure resistance Most common mutation Others mutations Abstract number South Africa d4T + 3TC + NNRTI LPV/r AZT ddI 2% 68% M184V 43% NRTI (TAMs); NNRTI PI (M46I, G48V, I54V, V82A, L90M) 661 Mali d4T + 3TC + NVP None 23% 50% 100% 662 Botswana AZT + ddI + d4T 3TC NA 78% 74% NRTI (TAMs) 52% 664 CROI 2007

DART TRIAL ZDV/3TC/TDF (n=300) Prevalence of mutations at 24 and 48 weeks in absence of virological monitoring Mutation Week 24 (n=24) Week 48 (n=41*) M184V 15 (62%) 32 (78%) K65R 3 (12%) 6 (15%) M41L 7 (29%) 17 41%) D67NG 9 (38%) 23 (56%) K70R 8 (33%) L210W 0 (0%) 3 (7%) T215FY 17 (41%) K219QEN 1 (4%) 9 (22%) Total TAMs: 0 1–3 4–6 10 (42%) 13 (54%) 11 (27%) 18 (44%) 12 (39%) TAM Group** I II I and II 5 (36%) 4 (11%) 2 (7%) 11 (37%) 17 (57%) Pillay et al. CROI 2007. Abstr. 642.

Summary Resistance develops following failure of therapy Resistance can be transmitted Improvements in ARV use reduces emergence and transmission of resistance Extensive resistance may develop in absence of monitoring of ARV use

Question: Risk of resistance is increased by: Mono and/or dual therapy prior to HAART Use of ritonavir boosted PIs Initiation of HAART at CD4 counts >200/L